In a multicenter , open-label , randomized , two-way crossover study , 132 patients with NIDDM received daily doses of 5 , 20 , or 40 mg of either glipizide-GITS or immediate-release glipizide for 8 weeks followed by 8 weeks of the alternate formulation .
